In the dynamic world of clinical research and pharmacovigilance (PV), the gold standard of patient safety lies in detecting potential safety signals before they develop into serious adverse events (AEs). One of the powerful tools towards achieving such standards is utilizing advanced technologies such as predictive analytics. Predictive analytics is the science of leveraging existing data to uncover patterns and forecast future outcomes.

Ichelon Pharma this blog explores how predictive analytics helps the Contract Research Organizations (CROs) and the Marketing Authorization Holders (MAHs) transform safety signal detection from a reactive process to a proactive strategy.

The Benefits of Predictive Analytics

As per signal management process, safety signal detection follows only after the AEs have been reported. Together with data from periodic safety reviews, the signals are assessed, and patterns are recognized. This format causes a delay between when a signal emerges and when it is ultimately detected. This could last for months and sometimes a year.

In contrast, predictive analytics leverages advanced technological tools like machine learning (ML) and natural language processing (NLP) for a faster and accurate prediction of safety signals. It builds intelligent systems that offer a paradigm shift by:

• Analyzing historical data to identify patterns

Predictive models examine clinical and post-marketing data to detect early warning signs. The CROs and MAHs can leverage these insights to develop proactive risk management strategies.

• Leveraging real-world evidence (RWE) along with clinical trial data

In the digital era, RWE from diverse sources provides valuable data on drug-AEs association. These sources include but are not limited to electronic health records (EHRs), registries, and patient-reported outcomes. Data from these sources, combined with the findings of clinical trials, provide a more comprehensive picture of a drug’s performance.

• Employing ML algorithms to detect subtle correlations that human reviewers might miss

Human reviewers may often miss identifying weak drug-AEs associations for reasons like comprehension bias, data overload, or problems with the reporting system. However, the advanced ML algorithms can analyze complex and multidimensional datasets with precision and even spot subtle drug-AEs correlations.

• Continuously monitoring new data to flag potential concerns 

The predictive analytics approach enables continuous surveillance of new data in real time. As soon as potential concerns are flagged, companies can prompt early investigations. For CROs and MAHs, this feature not only minimizes delays in signal detection but also supports faster, data-driven safety decisions.

Understanding Predictive Analytics

Predictive analytics has 2 major components:

1. Real-world data (RWD)
2. Cloud computing with big data architecture

• Real-World Data

The RWD lays a strong foundation to harness the benefits of predictive analytics. The three major sources of RWD are:

• Regulatory data from spontaneous reporting systems like the Food and Drug Administration Adverse Event Reporting System (FAERS) and EudraVigilance.

1. Clinical data from EHRs, patient registries, and claims data from RWE.
2. Patient-reported data from social media platforms, patient forums, and wearable devices.

Combining data from these diverse sources offers two major advantages:

1. It provides a larger pool of information for faster, more timely analysis.
2. It enables predicting risks in many unstudied patient populations that were excluded from controlled clinical trials.

For example, data from a social media platform may come from specific age groups or patients with comorbidities who were not studied in systematic clinical trials. However, successful prediction of safety signals depends on aggregating, cleaning, and standardizing disparate, often incomplete, or biased data from these varied sources.

• Cloud computing with big data architecture

The key highlight of cloud computing with big data architecture is predicting safety signals through real-time integration and analysis of vast and diverse datasets. The trained and validated ML and NLP algorithms are the backbone of cloud computing, facilitating the detection of safety signals quickly and with precision. Further, the cloud-based platforms facilitate global collaboration for sharing data and insights among CROs, MAHs, and regulatory bodies. Overall, these capabilities promote collective efforts toward proactive drug safety monitoring.

Implementing Predictive Analytics 

Implementing predictive analytics in your PV workflow requires better planning and preparation in terms of resources and teams that make the transition smooth and effective. The following are the essential preparation steps you should consider:

• Data preparation

Centralizing vast and diverse datasets is at the core of data preparation. Include multiple sources of AEs reporting: individual case safety reports (ICSRs), EHRs, clinical trial data, genomic data, and RWE. At times, data coming from some of these sources is unstructured or incomplete. In such cases, AEs have to be coded to their preferred term (PT) as per Medical Dictionary for Regulatory Activities (MedDRA). Further, in compliance with data regulation requirements, ensure that the data contains no identifiable information. Split the final data set into training and test data sets.

• ML model development

A good ML model has high sensitivity and a low risk of missing genuine safety signals. Therefore, select an appropriate model and train it on the training data set. The model learns patterns and relationships in drug-AEs pair frequency, dosage, duration, and more. A human reviewer may label or re-label the data that the model got wrong, and then use it again to retrain the model.

• Model performance evaluation 

The ML model has to be validated and optimized based on performance metrics, like prediction accuracy, precision, and recall. Choose the right metric based on the safety objective. A top-performing model has the following attributes:

1. Clearly identifies true and potentially true safety signals
2. Calculates a risk score for drug-AEs pairs
3. Performs well on a dataset it was not trained on to prove its ability to generalize

• Deployment and integration

To test how the model performs in a real-world conduct a controlled pilot test deployment. For smoother integration into the existing PV workflow, develop thorough recommendations. This can include human review steps for model outputs. These reviews are essential, especially for critical decisions. The model’s performance should be continuously monitored for data drift in production to ensure it remains accurate and reliable over time.

• Operationalization and governance

For a seamless transition to the new change, provide PV teams with educational and training support. Develop comprehensive training for end-users (e.g., PV scientists, case processors, physicians) and educational materials on how to use and interpret the model’s output. Designing and implementing a robust governance framework can ensure accountability and compliance with regulatory requirements.

Summary

Enhanced speed, accuracy, and scalability in drug safety monitoring are uncompromisable. Predictive analytics boosts these factors and transforms PV from a mandated compliance activity into a continuous value-driver for patient well-being. Transform your PV systems by investing in the infrastructure and talent necessary to leverage predictive analytics effectively.